Mogamulizumab became the first anti-CCR4 biologic approved in 2012 when Japan approved it for the treatment of relapsed or refractory CCR4+ adult T cell Leukemia-Lymphoma (ATLL) (18, 19, 23). Here, CCR4 is linked to lymphoma.